Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Bellevue Funds Lux - BB Biotech

+ Add to Watchlist

BBBIOCB:LX

462.24 CHF 5.63 1.20%

As of 09:08:00 ET on 04/24/2015.

Snapshot for Bellevue Funds Lux - BB Biotech (BBBIOCB)

Year To Date: +16.51% 3-Month: +21.70% 3-Year: +47.45% 52-Week Range: 248.90 - 490.45
1-Month: +1.20% 1-Year: +78.77% 5-Year: +24.20% Beta vs LUXXX: 0.88

Mutual Fund Chart for BBBIOCB

No chart data available.
  • BBBIOCB:LX 462.24
  • 1M
  • 1Y
Interactive BBBIOCB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for BBBIOCB

Bellevue Funds (Lux) - BB Biotech is an open-end investment fund incorporated in Luxembourg. The Fund's objective is long-term capital appreciation. The Fund invests mainly in equities and equity related securities of companies that are directly involved in the biotechnology sector. The focus is on companies that develop, research, and market various technologies and products in this sector.

Inception Date: 04-02-2009 Telephone: 41-44-267-67-00
Managers: DANIEL KOLLER
Web Site: www.bellevuegroup.com

Fundamentals for BBBIOCB

NAV (on 2015-04-24) 462.24
Assets (M) (on 2015-04-24) 109.75
Fund Leveraged N
Minimum Investment -
Minimum Subsequent Investment -

Dividends for BBBIOCB

No dividends reported

Fees & Expenses for BBBIOCB

Front Load -
Back Load 0.00
Current Mgmt Fee 1.60
Redemption Fee 0.00
12b1 Fee -
Expense Ratio -

Top Fund Holdings for BBBIOCB

Filing Date: 03/31/2015
Name Position Value % of Total
Biogen Inc 20,000 8,444,800 8.356%
Celgene Corp 63,000 7,262,640 7.186%
Gilead Sciences Inc 72,000 7,065,360 6.991%
Amgen Inc 30,866 4,933,930 4.882%
Alexion Pharmaceuticals Inc 20,746 3,595,282 3.557%
Regeneron Pharmaceuticals Inc 7,595 3,428,991 3.393%
Vertex Pharmaceuticals Inc 28,500 3,362,145 3.327%
Mylan NV 55,000 3,264,250 3.230%
Medivation Inc 24,300 3,136,401 3.103%
BioMarin Pharmaceutical Inc 25,000 3,115,500 3.083%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil